The 1st China Pharmaceutical Innovation Conference (CPIC), hosted by TONACEA, will be grandly held from July 22 to 24, 2026, at the National Exhibition and Convention Center (Shanghai).

Benchmarking the J.P. Morgan Healthcare Conference, CPIC aims to establish a new paradigm of "China Innovation – Global Partnerships – Shanghai Dealmaking." As the "premier window" for global capital and enterprises to gain insight into China's innovation ecosystem, and as the "core hub" for Chinese pharmaceutical companies to upgrade, go global, and connect with the world, CPIC is set to become the definitive barometer for annual investment and collaboration in the global health industry. The conference will feature dozens of dedicated sessions covering numerous hot topics and future directions in health industry innovation investment and globalization.

With the continuous enhancement of China's pharmaceutical innovation capabilities and the accelerated pace of global expansion, enterprises are facing increasing demand for professional services in areas such as licensing and collaboration, BD-driven globalization, capital markets, investment and financing, patent protection, and pharmaceutical compliance. Chinese pharmaceutical companies stand at a critical turning point from local innovation to global value realization. Against this backdrop, Fangda Partners' Life Sciences team and TONACEA are jointly hosting a special session themed "Legal Safeguards and Value Empowerment for the Globalization of Chinese Pharmaceutical Enterprises." The session will focus on cutting-edge legal issues in the pharmaceutical sector, including deal structure design and risk management for BD globalization, diversified financing pathways in domestic and international capital markets, key term arrangements in investment and financing transactions, global patent portfolio strategies and infringement response for innovative drugs, and localized compliance practices. The forum aims to build a deeply interactive collaborative ecosystem for participants, connecting diverse resources and professional expertise to jointly explore new sustainable, high-quality international market opportunities.

Scan the QR code to register now!
Limited-time early bird tickets at 40% off – grab yours now!!

About Fangda Partners

Founded in 1993, Fangda Partners is one of China's leading full-service law firms. With offices in Beijing, Guangzhou, Hong Kong, Nanjing, Shanghai, Shenzhen, and Singapore, the firm has over 800 lawyers. Fangda has deep industry expertise and extensive experience in the life sciences and healthcare sector, having long served global leading pharmaceutical companies, biotech firms, medical device companies, and various investment institutions. The firm provides comprehensive "one-stop" legal support across cross-border technology licensing, joint ventures and collaborations, mergers and acquisitions, financing, capital markets, intellectual property, and dispute resolution. Since 2019, Fangda's Life Sciences and Healthcare practice has been consistently ranked as Tier 1 by The Legal 500. Leveraging its profound understanding of China's regulatory environment and its international perspective, Fangda is committed to being the most trusted legal partner for clients in the life sciences and healthcare sector, helping Chinese innovation reach global markets.

Fangda Partners Delegation
(Listed in alphabetical order by surname)

Han Liang: Managing Partner – Practice areas: Antitrust investigation and litigation, antitrust compliance.

He Ning: Partner (Shanghai) – Practice areas: Corporate collaboration and licensing, life sciences and healthcare.

Jiang Qian: Partner (Beijing) – Practice areas: Corporate law, private equity, venture capital, M&A, foreign direct investment, and general corporate legal matters.

Li Na: Partner (Shanghai) – Practice areas: Licensing and commercialization transactions in life sciences, M&A, private financing, and overseas capital markets.

Li Run: Partner (Shanghai) – Practice areas: Investment and financing, M&A, foreign investment, capital markets, and general corporate legal matters.

Li Xiang: Partner (Beijing) – Practice areas: M&A, private equity investment, foreign direct investment, and general corporate legal matters.

Lin Sumiao: Partner (Beijing) – Practice areas: Fund investment, private equity, and M&A.

Liu Yiwei: Partner (Shanghai/Nanjing) – Practice areas: Capital markets, M&A, private financing, and general corporate matters.

Luo Deyuan (Lawrence Lo): Partner (Hong Kong) – Practice areas: Hong Kong capital markets, privatizations, and cross-border and international acquisitions.

Ma Lingjun: Partner (Shanghai) – Practice areas: Cross-border M&A, restructuring, securities, financial services.

Qin Lin: Partner (Shanghai) – Practice areas: Intellectual property litigation and prosecution, unfair competition, and IP consulting and management.

Shi Wei: Partner (Shanghai) – Practice areas: Corporate collaboration and licensing, life sciences and healthcare.

Murran Sun (Sun Muran): Partner (Shanghai) – Practice areas: Intellectual property litigation and licensing, antitrust litigation.

Wang Ya: Partner (Shanghai) – Practice areas: Corporate collaboration and licensing, life sciences and healthcare.

Zhang Yi: Partner (Shanghai) – Practice areas: Privacy and personal data protection, cybersecurity, regulatory compliance.

Zhong Qi: Partner (Shanghai) – Practice areas: Corporate M&A and strategic exits, private equity investment exits, joint ventures, capital markets, direct investment, overseas acquisitions, private equity fund formation, and corporate financing.

About TONACEA

TONACEA is a premier ecosystem platform in China's biomedical innovation sector. With over 20 years of deep engagement in China's innovative drug development, it has grown into a key organizational force driving China's pharmaceutical innovation and serves as a core hub connecting multinational pharmaceutical companies with local innovation.

TONACEA brings together multinational pharmaceutical companies, biotech firms, investment institutions, research institutes, and regulatory experts, establishing a high-end professional network and knowledge-sharing system that covers the entire R&D value chain. Its business encompasses industry summits, technical forums, customized corporate training, media communications, and strategic consulting. With multiple branches across China, TONACEA has built an operational network that extends nationwide. Its official WeChat account and video channel consistently deliver in-depth industry insights, with perspectives frequently cited by investors and media, earning recognition as a trusted authoritative source within the industry.